MX2023014668A - Un producto farmaceutico que contiene tasquinimod y un metodo para evaluar la pureza de dicho producto. - Google Patents
Un producto farmaceutico que contiene tasquinimod y un metodo para evaluar la pureza de dicho producto.Info
- Publication number
- MX2023014668A MX2023014668A MX2023014668A MX2023014668A MX2023014668A MX 2023014668 A MX2023014668 A MX 2023014668A MX 2023014668 A MX2023014668 A MX 2023014668A MX 2023014668 A MX2023014668 A MX 2023014668A MX 2023014668 A MX2023014668 A MX 2023014668A
- Authority
- MX
- Mexico
- Prior art keywords
- tasquinimod
- assessing
- product
- purity
- pharmaceutical composition
- Prior art date
Links
- ONDYALNGTUAJDX-UHFFFAOYSA-N tasquinimod Chemical compound OC=1C=2C(OC)=CC=CC=2N(C)C(=O)C=1C(=O)N(C)C1=CC=C(C(F)(F)F)C=C1 ONDYALNGTUAJDX-UHFFFAOYSA-N 0.000 title abstract 7
- 229950001899 tasquinimod Drugs 0.000 title abstract 7
- 238000000034 method Methods 0.000 title abstract 4
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 229940127557 pharmaceutical product Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- VBQKTNWAJUPMIU-UHFFFAOYSA-N CN(C1=CC=CC(OC)=C1C(O)=C1CC(C(N(C)C2=CC=CC(OC)=C22)=O)=C2O)C1=O Chemical compound CN(C1=CC=CC(OC)=C1C(O)=C1CC(C(N(C)C2=CC=CC(OC)=C22)=O)=C2O)C1=O VBQKTNWAJUPMIU-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21183481 | 2021-07-02 | ||
| PCT/EP2022/068063 WO2023275248A1 (en) | 2021-07-02 | 2022-06-30 | A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023014668A true MX2023014668A (es) | 2024-01-12 |
Family
ID=76764937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023014668A MX2023014668A (es) | 2021-07-02 | 2022-06-30 | Un producto farmaceutico que contiene tasquinimod y un metodo para evaluar la pureza de dicho producto. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240277693A1 (https=) |
| EP (1) | EP4363404A1 (https=) |
| JP (1) | JP2024524158A (https=) |
| KR (1) | KR20240029029A (https=) |
| CN (1) | CN117500790A (https=) |
| AU (1) | AU2022303084A1 (https=) |
| CA (1) | CA3221689A1 (https=) |
| IL (1) | IL309486A (https=) |
| MX (1) | MX2023014668A (https=) |
| WO (1) | WO2023275248A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024306742A1 (en) * | 2023-06-28 | 2025-12-04 | Active Biotech Ab | Quinoline carboxamides for use in the treatment of mpn |
| WO2025228998A1 (en) * | 2024-04-30 | 2025-11-06 | Institut National de la Santé et de la Recherche Médicale | Use of hdac4 inhibitors for the treatment of melanoma |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| SE0002320D0 (sv) | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
| SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| SG186430A1 (en) | 2010-07-09 | 2013-01-30 | Active Biotech Ab | Method for manufacturing of quinoline-3-carboxamides |
| EP2537517A1 (en) | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
| CN105367492B (zh) * | 2014-08-28 | 2018-07-03 | 杭州普晒医药科技有限公司 | 他喹莫德的晶型及其制备方法、其药物组合物和用途 |
| JP6647287B2 (ja) | 2014-09-23 | 2020-02-14 | アクティブ バイオテック エイビー | 多発性骨髄腫の治療に使用するためのキノリンカルボキサミド |
| MX379401B (es) | 2014-11-19 | 2025-03-11 | Active Biotech Ab | Carboxamidas de quinolina para usarse en el tratamiento de leucemia. |
| EP3067062A1 (en) | 2015-03-13 | 2016-09-14 | Ipsen Pharma S.A.S. | Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament |
| BR112023000892A2 (pt) | 2020-07-23 | 2023-02-07 | Univ Erasmus Med Ct Rotterdam | Inibidor de uma proteína s100 para uso na prevenção ou tratamento de uma neoplasia mieloproliferativa, agente e método para identificar um indivíduo que sofre de uma neoplasia mieloproliferativa, e, métodos para identificar um indivíduo em risco de desenvolver mielofibrose e que se beneficie de um tratamento com um inibidor |
-
2022
- 2022-06-30 AU AU2022303084A patent/AU2022303084A1/en active Pending
- 2022-06-30 CN CN202280043401.8A patent/CN117500790A/zh active Pending
- 2022-06-30 JP JP2023578067A patent/JP2024524158A/ja active Pending
- 2022-06-30 US US18/571,472 patent/US20240277693A1/en active Pending
- 2022-06-30 EP EP22741222.8A patent/EP4363404A1/en active Pending
- 2022-06-30 MX MX2023014668A patent/MX2023014668A/es unknown
- 2022-06-30 KR KR1020247002056A patent/KR20240029029A/ko active Pending
- 2022-06-30 CA CA3221689A patent/CA3221689A1/en active Pending
- 2022-06-30 IL IL309486A patent/IL309486A/en unknown
- 2022-06-30 WO PCT/EP2022/068063 patent/WO2023275248A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP4363404A1 (en) | 2024-05-08 |
| KR20240029029A (ko) | 2024-03-05 |
| WO2023275248A1 (en) | 2023-01-05 |
| AU2022303084A1 (en) | 2024-01-25 |
| US20240277693A1 (en) | 2024-08-22 |
| CA3221689A1 (en) | 2023-01-05 |
| CN117500790A (zh) | 2024-02-02 |
| IL309486A (en) | 2024-02-01 |
| JP2024524158A (ja) | 2024-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023008716A (es) | Compuesto de camptotecina, metodo de preparacion del mismo y aplicacion del mismo. | |
| ZA202308118B (en) | Cdk inhibitor | |
| MX2021002321A (es) | Nuevos metodos. | |
| TW200619220A (en) | New hydrates and polymorphs of 4-[[(7r)-8-cyclopentyl-7-ethyl-5, 6, 7, 8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-mithoxy-n-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament | |
| MXPA05003253A (es) | Nuevos derivados de pirimidinamida y el uso de los mismos. | |
| MY199967A (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| PH12020500091A1 (en) | Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7] annulene-2-carboxylic acid and its use for the treatment of cancer | |
| TW200505924A (en) | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | |
| AU2003298094A1 (en) | Medicinal arylethanolamine compounds | |
| TW200730502A (en) | Isoquinoline aminopyrazole derivatives, their manufacture and use as pharmaceutical agents | |
| MX2023014668A (es) | Un producto farmaceutico que contiene tasquinimod y un metodo para evaluar la pureza de dicho producto. | |
| SA519401614B1 (ar) | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب | |
| WO2003087049A3 (de) | Arzneimittelkombinationen enthaltend heterocyclische verbindungen und ein neues anticholinergikum | |
| PH12022550441A1 (en) | Azaheteroaryl compound and application thereof | |
| ZA202210640B (en) | Deuterated oxophenylarsine compound and use thereof | |
| MX2021002042A (es) | Inhibidores de arginasa y sus metodos de uso. | |
| IL163951A0 (en) | New heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in medicine | |
| MY207759A (en) | Pharmaceutical drug containing heterocyclidene acetamide derivative | |
| MX2022006052A (es) | Inhibidores de la caspasa 6 y usos de los mismos. | |
| TW200606164A (en) | New compounds | |
| TW200800984A (en) | New compounds | |
| MX2022009898A (es) | Compuesto de dihidronaftiridinona y metodo de preparacion del mismo y uso medico del mismo. | |
| MX2022001647A (es) | Terapia de combinacion con vildagliptina y metformina. | |
| WO2020154420A3 (en) | Amino acid derivatives for the treatment of inflammatory diseases | |
| UA66932C2 (en) | Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine |